PolyPid Ltd. (NASDAQ:PYPD) Given Consensus Recommendation of “Moderate Buy” by Analysts

Shares of PolyPid Ltd. (NASDAQ:PYPD) have earned an average rating of “Moderate Buy” from the seven research firms that are covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, five have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month price target among brokers that have covered the stock in the last year is $12.40.

Several research firms recently commented on PYPD. Wall Street Zen raised shares of PolyPid from a “sell” rating to a “hold” rating in a research note on Sunday, November 16th. Weiss Ratings reiterated a “sell (e+)” rating on shares of PolyPid in a research report on Wednesday, October 8th. Craig Hallum reissued a “buy” rating and set a $13.00 price objective (down from $15.00) on shares of PolyPid in a research note on Thursday, August 14th. HC Wainwright reaffirmed a “buy” rating and set a $13.00 target price on shares of PolyPid in a research report on Wednesday, August 13th. Finally, Roth Capital reduced their target price on PolyPid from $10.00 to $9.00 and set a “buy” rating for the company in a report on Thursday, November 13th.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the company. AIGH Capital Management LLC raised its holdings in shares of PolyPid by 27.0% during the second quarter. AIGH Capital Management LLC now owns 1,194,108 shares of the company’s stock valued at $4,215,000 after acquiring an additional 253,727 shares during the period. Lumbard & Kellner LLC acquired a new position in PolyPid in the 2nd quarter worth approximately $135,000. Finally, BNP Paribas Financial Markets grew its position in PolyPid by 56.1% during the 3rd quarter. BNP Paribas Financial Markets now owns 9,734 shares of the company’s stock worth $32,000 after purchasing an additional 3,500 shares in the last quarter. 26.47% of the stock is currently owned by institutional investors and hedge funds.

PolyPid Stock Up 0.8%

NASDAQ:PYPD opened at $3.63 on Friday. The business’s 50-day moving average price is $3.50 and its 200 day moving average price is $3.38. PolyPid has a 52-week low of $2.30 and a 52-week high of $3.93. The firm has a market cap of $57.72 million, a P/E ratio of -1.22 and a beta of 1.53.

PolyPid (NASDAQ:PYPD) last posted its quarterly earnings data on Wednesday, November 12th. The company reported ($0.37) earnings per share for the quarter, beating the consensus estimate of ($0.54) by $0.17. Sell-side analysts expect that PolyPid will post -1.79 EPS for the current year.

About PolyPid

PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions.